Representative Marjorie Taylor Greene (R-Georgia) recently bought shares of Amgen Inc. NASDAQ: AMGN. In a filing disclosed on May 06th, the Representative disclosed that they had bought between $1,001 and $15,000 in Amgen stock on May 5th. The trade occurred in the Representative's "MARJORIE IRA" account.
Representative Marjorie Taylor Greene also recently made the following trade(s):
- Purchased $1,001 - $15,000 in shares of AbbVie NYSE: ABBV on 5/5/2025.
- Purchased $1,001 - $15,000 in shares of Occidental Petroleum NYSE: OXY on 5/5/2025.
- Purchased $1,001 - $15,000 in shares of Paychex NASDAQ: PAYX on 5/5/2025.
- Purchased $1,001 - $15,000 in shares of MercadoLibre NASDAQ: MELI on 5/5/2025.
- Purchased $1,001 - $15,000 in shares of Starbucks NASDAQ: SBUX on 5/5/2025.
- Purchased $1,001 - $15,000 in shares of BP NYSE: BP on 5/5/2025.
- Purchased $1,001 - $15,000 in shares of Gilead Sciences NASDAQ: GILD on 5/5/2025.
- Purchased $1,001 - $15,000 in shares of BHP Group NYSE: BHP on 5/5/2025.
- Purchased $1,001 - $15,000 in shares of Advanced Micro Devices NASDAQ: AMD on 5/5/2025.
- Purchased $1,001 - $15,000 in shares of Alphabet NASDAQ: GOOG on 5/5/2025.
Amgen Stock Performance
Shares of NASDAQ:AMGN traded down $4.18 during midday trading on Tuesday, reaching $270.58. 667,021 shares of the company traded hands, compared to its average volume of 3,138,628. The firm's fifty day moving average price is $295.24 and its two-hundred day moving average price is $289.21. The firm has a market capitalization of $145.49 billion, a price-to-earnings ratio of 35.84, a price-to-earnings-growth ratio of 2.63 and a beta of 0.51. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $346.85.
Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $4.18 by $0.72. The firm had revenue of $8.15 billion for the quarter, compared to the consensus estimate of $8.05 billion. Amgen had a net margin of 12.24% and a return on equity of 176.32%. The company's revenue for the quarter was up 9.4% on a year-over-year basis. During the same period in the prior year, the firm posted $3.96 earnings per share. On average, equities analysts expect that Amgen Inc. will post 20.62 earnings per share for the current year.
Amgen Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be given a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $9.52 annualized dividend and a dividend yield of 3.52%. Amgen's dividend payout ratio is currently 86.86%.
Hedge Funds Weigh In On Amgen
Large investors have recently bought and sold shares of the stock. Centricity Wealth Management LLC purchased a new stake in shares of Amgen during the 4th quarter worth $25,000. Pinney & Scofield Inc. acquired a new stake in shares of Amgen in the fourth quarter valued at approximately $26,000. First Pacific Financial raised its position in shares of Amgen by 304.5% during the 1st quarter. First Pacific Financial now owns 89 shares of the medical research company's stock worth $28,000 after purchasing an additional 67 shares during the last quarter. Ritter Daniher Financial Advisory LLC DE grew its holdings in Amgen by 66.2% during the 4th quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock valued at $33,000 after buying an additional 51 shares during the last quarter. Finally, Synergy Investment Management LLC acquired a new position in shares of Amgen in the fourth quarter valued at approximately $34,000. Institutional investors and hedge funds own 76.50% of the company's stock.
Wall Street Analyst Weigh In
Several brokerages have recently commented on AMGN. UBS Group reaffirmed a "neutral" rating and set a $315.00 price objective (down from $319.00) on shares of Amgen in a research note on Friday, May 2nd. Bank of America upped their price objective on Amgen from $275.00 to $294.00 and gave the company an "underperform" rating in a research report on Wednesday, March 5th. Johnson Rice set a $294.00 price target on Amgen in a research note on Wednesday, March 5th. Royal Bank of Canada cut their target price on shares of Amgen from $324.00 to $320.00 and set an "outperform" rating for the company in a research report on Friday, May 2nd. Finally, Cantor Fitzgerald assumed coverage on shares of Amgen in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $305.00 price objective for the company. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, ten have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $310.23.
Check Out Our Latest Analysis on Amgen
Insiders Place Their Bets
In other news, EVP David M. Reese sold 25,225 shares of the business's stock in a transaction on Friday, February 21st. The shares were sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the completion of the sale, the executive vice president now directly owns 36,922 shares of the company's stock, valued at $11,240,533.68. The trade was a 40.59% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.76% of the stock is owned by corporate insiders.
About Representative Greene
Marjorie Taylor Greene (Republican Party) is a member of the U.S. House, representing Georgia's 14th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027.
Greene (Republican Party) is running for re-election to the U.S. House to represent Georgia's 14th Congressional District. She declared candidacy for the 2026 election.
Amgen Company Profile
(
Get Free Report)
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
Featured Articles
Before you consider Amgen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.
While Amgen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
